KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Operations: 2011-2025

Historic Cash from Operations for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to -$14.6 million.

  • Sarepta Therapeutics' Cash from Operations rose 79.37% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$244.6 million, marking a year-over-year increase of 30.60%. This contributed to the annual value of -$205.8 million for FY2024, which is 58.92% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Cash from Operations stood at -$14.6 million, which was down 105.58% from $261.3 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Cash from Operations high stood at $261.3 million for Q2 2025, and its period low was -$583.4 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$70.7 million (2024), whereas its average is -$94.9 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Cash from Operations plummeted by 215.05% in 2022 and then surged by 1,649.01% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Cash from Operations stood at -$29.3 million in 2021, then tumbled by 215.05% to -$92.4 million in 2022, then surged by 40.84% to -$54.7 million in 2023, then spiked by 268.41% to $92.0 million in 2024, then spiked by 79.37% to -$14.6 million in 2025.
  • Its last three reported values are -$14.6 million in Q3 2025, $261.3 million for Q2 2025, and -$583.4 million during Q1 2025.